Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, Dan Moldoveanu et al.|Clinical Cancer Research|2018Cited by 76